Entera Bio and OPKO Health Collaborate on Innovative Treatment for Obesity and Metabolic Conditions

Entera Bio and OPKO Health are collaborating on an innovative treatment for obesity and metabolic conditions. The treatment, OPK-88006, is a dual agonist GLP-1/glucagon peptide. The companies are advancing both a once-daily tablet and a weekly subcutaneous injection form of the drug. An application for Investigational New Drug status is slated for submission to the FDA within the year. Analysts have a high estimate of $10.00 and a low estimate of $10.00, with an average target price of $10.00, indicating an upside of 410.20% from the current price of $1.96. The average brokerage recommendation is 2.0, indicating "Outperform" status.